Articles producció científica> Medicina i Cirurgia

SEOM clinical guidelines for the treatment of follicular non-Hodgkin’s lymphoma

  • Identification data

    Identifier: imarina:2309056
    Handle: http://hdl.handle.net/20.500.11797/imarina2309056
  • Authors:

    Provencio Pulla, Mariano
    Alfaro Lizaso, J
    Cruz Merino, L de la
    Gumà Padró, Josep
    Quero Blanco, Cristina
    Gómez Codina, José
    Llanos Muñoz, Marta
    Martínez Banaclocha, Natividad
    Rodríguez Abreu, Delvys
    Rueda Domínguez, Antonio
  • Others:

    Author, as appears in the article.: Provencio Pulla, Mariano; Alfaro Lizaso, J; Cruz Merino, L de la; Gumà Padró, Josep; Quero Blanco, Cristina; Gómez Codina, José; Llanos Muñoz, Marta; Martínez Banaclocha, Natividad; Rodríguez Abreu, Delvys; Rueda Domínguez, Antonio
    Department: Medicina i Cirurgia
    URV's Author/s: Gumà Padró, José
    Keywords: Hashtag Etiqueta «#» @uroweb @residentesaeu @infoAeu
    Abstract: Follicular non-Hodgkin’s lymphoma (FL) is a nodal B lymphoid malignancy that originates from the germinal center of a lymph node. FL is the second most frequent lymphoma subtype. The course of the disease is usually characterised by a typically indolent clinical course, with a median survival rate of 8–10 years, although most patients relapse after treatment. Diagnosis should always be based on a surgical specimen like an excisional node lymph biopsy. The first-line treatment of FL will depend of extension disease, tumour burden, patient symptoms, performance status and also patient decision. The addition of rituximab to conventional chemotherapy has improved ORR, PFS and OS. As first line in patients that need treatment, a combination of chemotherapy with rituximab induction followed by 2 years of rituximab maintenance is the best option. High-dose chemotherapy with autologous stem-cell transplantation in first line has not shown improvement and is not recommended as first-line therapy. Before any treatment decision in relapsed patients, a repeat biopsy is mandatory to rule out a transformation into large cell aggressive lymphoma. Standard treatment is controversial, depends on the efficacy of prior treatment, duration of the time-to-relapse, patient’s age and histological findings at relapse.
    Thematic Areas: Saúde coletiva Oncology Odontología Medicine (miscellaneous) Medicina veterinaria Medicina ii Medicina i Farmacia Engenharias ii Ciências biológicas ii Ciências biológicas i Cancer research Biotecnología
    licence for use: https://creativecommons.org/licenses/by/3.0/es/
    ISSN: 1699048X
    Author's mail: jose.guma@urv.cat
    Author identifier: 0000-0001-7541-9832
    Record's date: 2023-04-15
    Papper version: info:eu-repo/semantics/publishedVersion
    Link to the original source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689757/
    Licence document URL: http://repositori.urv.cat/ca/proteccio-de-dades/
    Papper original source: Clinical & Translational Oncology. 17 (12): 1014,1019-1019
    APA: Provencio Pulla, Mariano; Alfaro Lizaso, J; Cruz Merino, L de la; Gumà Padró, Josep; Quero Blanco, Cristina; Gómez Codina, José; Llanos Muñoz, Marta; (2015). SEOM clinical guidelines for the treatment of follicular non-Hodgkin’s lymphoma. Clinical & Translational Oncology, 17(12), 1014,1019-1019
    Article's DOI: 10.1007/s12094-015-1437-1
    Entity: Universitat Rovira i Virgili
    Journal publication year: 2015
    Publication Type: Journal Publications
  • Keywords:

    Cancer Research,Medicine (Miscellaneous),Oncology
    Saúde coletiva
    Oncology
    Odontología
    Medicine (miscellaneous)
    Medicina veterinaria
    Medicina ii
    Medicina i
    Farmacia
    Engenharias ii
    Ciências biológicas ii
    Ciências biológicas i
    Cancer research
    Biotecnología
  • Documents:

  • Cerca a google

    Search to google scholar